Monday June 26th 2017

Archive for March, 2011

MS sufferer’s family forced to pay for operation in Egypt

MS sufferer’s family forced to pay for operation in Egypt

THE family of a woman who suffers with Multiple Sclerosis (MS) paid thousands of pounds for her to travel to Egypt for surgery because the “life-changing” treatment is not available on the NHS. Carole and Morgan Lloyd, from Carmarthenshire, said their daughter, Teresa, [Read More]

Patients seek support for new treatment

Patients seek support for new treatment

During a recent visit to a doctor, Vickie Butler was given some reassurance in her struggle to cope with multiple sclerosis. “‘Don’t worry,’ the doctor told me.’ We’ll have a cure for MS soon,'” she said. “But I don’t [Read More]

“We are sorry”

“We are sorry”

A member of the Alberta chapter of the MS Society of Canada is apologizing, saying the society should have been more supportive of the controversial CCSVI treatment. Speaking to CTV News at the society’s 30th annual awards banquet Saturday afternoon, an MS Society [Read More]

 Page 1 of 6  1  2  3  4  5 » ...  Last » 

Latest Topics

Are static and functional balance abilities related in individuals with Multiple Sclerosis? – Pau M, Porta M, Coghe G, Corona F, Pilloni G, Lorefice…

Are static and functional balance abilities related in individuals with Multiple Sclerosis? – Pau M, Porta M, Coghe G, Corona F, Pilloni G, Lorefice…

BACKGROUND: In people with Multiple Sclerosis (pwMS), balance assessment is essential in estimating the risk of falls, [Read More]

CHMP Recommends Cladribine (Mavenclad) for Multiple Sclerosis CHMP Recommends Cladribine (Mavenclad) for Multiple Sclerosis

CHMP Recommends Cladribine (Mavenclad) for Multiple Sclerosis CHMP Recommends Cladribine (Mavenclad) for Multiple Sclerosis

The European Medicines Agency ’ s Committee for Medicinal Products for Human Use recommends approval of cladribine to [Read More]

Germany’s Merck gets EU backing for oral MS drug

Germany’s Merck gets EU backing for oral MS drug

FRANKFURT (Reuters) - Germany's Merck KGaA has won a key recommendation to become a late entrant to the market for oral [Read More]

New data at EAN show Roche ’s OCREVUS (ocrelizumab) significantly reduced multiple measures of disease progression in relapsing and primary…

New data at EAN show Roche ’s OCREVUS (ocrelizumab) significantly reduced multiple measures of disease progression in relapsing and primary…

Roche announced today that new post-hoc analyses from the OCREVUS ™ (ocrelizumab) Phase III clinical trial programme [Read More]

MS Society Hosts Joint Congressional Briefing on the Value of Rehabilitation

MS Society Hosts Joint Congressional Briefing on the Value of Rehabilitation

/About-the-Society/News/Society-Hosts-Joint-Congressional-Briefing-on-the [Read More]